WallStSmart

Janus Living, Inc. (JAN)vsWelltower Inc (WELL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Welltower Inc generates 1695% more annual revenue ($11.77B vs $655.41M). WELL leads profitability with a 12.0% profit margin vs -0.0%. WELL earns a higher WallStSmart Score of 57/100 (C).

JAN

Avoid

32

out of 100

Grade: F

Growth: 8.0Profit: 3.0Value: 5.0Quality: 5.3
Piotroski: 4/9Altman Z: 1.64

WELL

Buy

57

out of 100

Grade: C

Growth: 10.0Profit: 5.5Value: 2.0Quality: 7.0
Piotroski: 4/9Altman Z: 1.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for JAN.

WELLSignificantly Overvalued (-78.3%)

Margin of Safety

-78.3%

Fair Value

$116.05

Current Price

$200.84

$84.79 premium

UndervaluedFair: $116.05Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JAN2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
34.5%10/10

Revenue surging 34.5% year-over-year

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

WELL3 strengths · Avg: 9.7/10
Revenue GrowthGrowth
38.3%10/10

Revenue surging 38.3% year-over-year

EPS GrowthGrowth
157.9%10/10

Earnings expanding 157.9% YoY

Market CapQuality
$137.90B9/10

Large-cap with strong market position

Areas to Watch

JAN4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.644/10

Distress zone — elevated risk

Operating MarginProfitability
0.5%3/10

Operating margin of 0.5%

Return on EquityProfitability
-0.1%2/10

ROE of -0.1% — below average capital efficiency

WELL4 concerns · Avg: 2.3/10
Return on EquityProfitability
3.2%3/10

ROE of 3.2% — below average capital efficiency

PEG RatioValuation
3.622/10

Expensive relative to growth rate

P/E RatioValuation
94.4x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.202/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : JAN

The strongest argument for JAN centers on Revenue Growth, Price/Book. Revenue growth of 34.5% demonstrates continued momentum.

Bull Case : WELL

The strongest argument for WELL centers on Revenue Growth, EPS Growth, Market Cap. Revenue growth of 38.3% demonstrates continued momentum.

Bear Case : JAN

The primary concerns for JAN are EPS Growth, Altman Z-Score, Operating Margin.

Bear Case : WELL

The primary concerns for WELL are Return on Equity, PEG Ratio, P/E Ratio. A P/E of 94.4x leaves little room for execution misses.

Key Dynamics to Monitor

JAN profiles as a hypergrowth stock while WELL is a growth play — different risk/reward profiles.

WELL is growing revenue faster at 38.3% — sustainability is the question.

WELL generates stronger free cash flow (282M), providing more financial flexibility.

Monitor REIT - RESIDENTIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WELL scores higher overall (57/100 vs 32/100) and 38.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Janus Living, Inc.

REAL ESTATE · REIT - RESIDENTIAL · USA

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for pain management. The company is headquartered in Las Vegas, Nevada.

Welltower Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Welltower Inc. is a real estate investment trust that invests in healthcare infrastructure.

Visit Website →

Want to dig deeper into these stocks?